CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies

9:30 am - Tuesday 9th March 2027

  • Understanding the 2027 ADC landscape and how the bar has been raised to develop and deliver ADCs with meaningful patient impact
  • Outlining the future opportunities and applications on the horizon for ADCs to achieve target differentiation and clinical safety
  • Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
  • With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?

Speakers:

Chief Scientific Officer
Iksuda Therapeutics
Chief Executive Officer
Araris Biotech
Chief Executive Officer
Oxford Biotherapeutics
Global Commercial Head Oncology Pipeline
Boehringer Ingelheim
Chief Executive Officer
Iksuda Therapeutics